Subsequently compounds have recently been produced that interact with PRMT5 when bound to MTA, and which selectively target MTAP-negative cancer cells to varying degrees or elicit a synergistic effect in a MTAP-negative background (88, 89). This evidence concerns the gene PRMT5 and cancer.